Gland Pharma (NSE:GLAND) Scaled Net Operating Assets: N/A (As of Mar. 2026)


NSE:GLAND Gland Pharma Ltd NSE:GLAND
83 GF Score
Price ₹2,314.80
GF Value ₹2,125.65
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Gland Pharma Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Gland Pharma's operating assets for the quarter that ended in Mar. 2026 was ₹90,780 Mil. Gland Pharma's operating liabilities for the quarter that ended in Mar. 2026 was ₹18,693 Mil. Gland Pharma's Total Assets for the quarter that ended in Dec. 2025 was ₹0 Mil. Therefore, Gland Pharma's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.


Gland Pharma Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Scaled Net Operating Assets Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only 0.61 0.54 0.82 0.61 0.64

Gland Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:GLAND vs ZTS: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gland Pharma Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Scaled Net Operating Assets falls into.


NSE:GLAND
83GF Score
Gland Pharma Ltd NSE:GLAND
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Gland Pharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(90780.01-18693.08)/112249.2
=0.64

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=125108.48 - 34328.47
=90780.01

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=21528.98 - 932.27 - 1903.63
=18693.08

Gland Pharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(90780.01-18693.08)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=125108.48 - 34328.47
=90780.01

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=21528.98 - 932.27 - 1903.63
=18693.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,314.80 is trading 8.9% above its estimated GF Value™ of ₹2,125.65. GuruFocus considers Gland Pharma to be Fairly Valued.

Key valuation signals for NSE:GLAND:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹2,125.65 vs. price of ₹2,314.80 (8.9% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score

Get the complete analysis for NSE:GLAND

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,314.80
Price
₹2,125.65
GF Value